Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cara Therapeutic
CARACurrent price
0.37 USD
+0.0001 USD (+0.03%)
Last closed
0.37 USD
Company
www.caratherapeutics.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
18 835 882 USD
Yield for 12 month
-87.91 %
1Y
3Y
5Y
10Y
15Y
CARA
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Address: 400 Atlantic Street, Stamford, CT, United States, 06901
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2.8 USDP/E ratio
–Dividend Yield
–Current Year
+20 968 000 USD
Last Year
+41 867 000 USD
Current Quarter
+2 135 000 USD
Last Quarter
+3 004 000 USD
Current Year
+14 535 000 USD
Last Year
+34 601 000 USD
Current Quarter
+1 473 000 USD
Last Quarter
+2 314 000 USD
Key Figures CARA
1 year
3 years
5 years
10 years
EBITDA
-120 867 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-62.2 %
PEG Ratio
–
Return On Equity TTM
-147.29 %
Wall Street Target Price
2.8 USD
Revenue TTM
16 938 000 USD
Book Value
0.55 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-65.4 %
Dividend Yield
–
Gross Profit TTM
-56 141 000 USD
Earnings per share
-2.26 USD
Diluted Eps TTM
-2.26 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CARA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CARA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:2
Payout Ratio
–
Last Split Date
16.01.2014
Dividend Date
–
Stock Valuation CARA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
12.0452
Price Sales TTM
1.9917
Enterprise Value EBITDA
0.4497
Price Book MRQ
0.7316
Financials CARA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CARA
For 52 weeks
0.24 USD
3.45 USD
50 Day MA
0.51 USD
Shares Short Prior Month
2 272 266
200 Day MA
0.8 USD
Short Ratio
1.47
Shares Short
1 927 481
Short Percent
4.1 %
BeatStart